PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS Real world ischaemic event reduction with PCSK9i mAbs Inclisiran role in plaque stabilisation Discontinuing PCSK9i leads to increased MACE V-MONO trial of inclisiran monotherapy meets primary endpoints

Latest News Updates

David Hare Articles

PCSK9 inhibition in heart failure

PCSK9 inhibition in heart failure

Prof David Hare University of Melbourne and Director of Secondary Prevention Programs at Austin Health, Melbourne, Australia Whether lowering LDL cholesterol with a PCSK9 inhibitor on top of statin therapy confers benefit – or harm – in heart failure patients was tested in this latest…

Posted on 9 February 2022 | Posted by David Hare | Posted in From the Editors

Depression, Cardiovascular Disease and Adherence

Depression, Cardiovascular Disease and Adherence

David Hare & Samia R Toukhsati, University of Melbourne, Australia This editorial discusses the interrelationship between cardiovascular disease and depression and poses the question: Is depression a key modulator of patient adherence and clinical outcome? “Depression” can refer to anything from feeling transiently unhappy through…

Posted on 7 November 2017 | Posted by David Hare, Samia R Toukhsati | Posted in From the Editors

An update on cardiovascular disease, depression and adherence

An update on cardiovascular disease, depression and adherence

Reports from the 7th Expert Meeting of PCSK9 Forum David Hare

Posted on 7 November 2017 | Posted by David Hare | Posted in Webcasts, 7th Closed Scientific Expert Meeting of the Editorial Board

Many key barriers are amenable to change; new strategies are needed

Many key barriers are amenable to change; new strategies are needed

General considerations: David L. Hare, University of Melbourne Australia

Posted on 5 October 2016 | Posted by David Hare | Posted in Hot topics, Webcasts, 5th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

Lib Therapeutics

Novartis

Sanofi

© Copyright 2024 PCSK9 Forum. All rights reserved